Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Serina Therapeutics (SER) Share-based Compensation (2018 - 2025)

Serina Therapeutics (SER) has disclosed Share-based Compensation for 8 consecutive years, with $948000.0 as the latest value for Q4 2025.

  • Quarterly Share-based Compensation fell 63.47% to $948000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.8 million through Dec 2025, up 22.12% year-over-year, with the annual reading at $3.8 million for FY2025, 46.17% up from the prior year.
  • Share-based Compensation hit $948000.0 in Q4 2025 for Serina Therapeutics, down from $2.8 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $2.8 million in Q3 2025 to a low of -$927000.0 in Q2 2025.
  • Historically, Share-based Compensation has averaged $484555.6 across 5 years, with a median of $224000.0 in 2022.
  • Biggest five-year swings in Share-based Compensation: surged 2550.0% in 2024 and later plummeted 302.4% in 2025.
  • Year by year, Share-based Compensation stood at $263000.0 in 2021, then tumbled by 56.65% to $114000.0 in 2022, then crashed by 64.91% to $40000.0 in 2023, then skyrocketed by 6387.5% to $2.6 million in 2024, then plummeted by 63.47% to $948000.0 in 2025.
  • Business Quant data shows Share-based Compensation for SER at $948000.0 in Q4 2025, $2.8 million in Q3 2025, and -$927000.0 in Q2 2025.